Equities

Mantex AB

Mantex AB

Actions
  • Price (SEK)0.2365
  • Today's Change0.007 / 3.05%
  • Shares traded332.88k
  • 1 Year change-61.47%
  • Beta2.6990
Data delayed at least 15 minutes, as of Apr 26 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mantex AB is a Sweden-based company that is engaged in development, production and sale of equipment for rapid and non-destructive material analysis of organic material by the use of X-rays of several energies. The products apply to biomass, including wood, wood chips, agricultural products and residues and are used in industrial processes for the determination of the dry content or energy content in materials within such industries as paper, bioenergy, process and food. The Company offers the following products: Biofuel Analyzer, which assesses the quality of wood-based biofuels; Flow Scanner, which applies to wood chips for pulp and paper production; and Log Scanner, which is used for foreign object detection and log measurements.

  • Revenue in SEK (TTM)6.83m
  • Net income in SEK-16.05m
  • Incorporated1998
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AlphaHelix Molecular Dignstics AB (publ)23.85m-11.38m20.03m13.00--2.52--0.8399-0.1794-0.17940.37620.12561.144.085.711,834,817.00-54.52-6.39-79.18-10.51-0.1479---47.69-4.090.9424--0.00---23.107.83-326.08---4.64--
Sarsys AB42.39m-5.55m22.85m22.00--4.26--0.539-0.459-0.4593.510.44340.931.399.71---12.18-7.82-31.94-14.7563.1062.82-13.09-8.890.3569-2.960.6867--22.96-5.5142.97---51.00--
Scape Technologies A/S-156.63bn-156.63bn40.68m-----------------------------76.36---98.26---16.17---373.75---------26.570.0172-27.59------
Miris Holding AB (publ)16.26m-11.31m43.62m10.00------2.68-0.2732-0.27320.3928-0.12860.8539-0.11297.341,729,681.00-59.41-59.61-186.33-111.08102.1286.68-69.57-103.610.2251-11.97-----17.192.53-20.86------
Mantex AB6.83m-16.05m59.33m----2.73--8.69-0.0788-0.07880.03320.08670.23980.248842.92---56.37-64.71-64.06-76.8279.0563.54-235.05-300.724.43-69.720.1601--373.264.57-3.37------
Insplorion AB2.84m-22.71m65.42m12.00--2.52--23.03-2.52-2.520.18711.090.0797-2.105.58218,538.50-63.67-29.27-74.89-34.48238.58260.36-799.37-791.031.63--0.0409---2.70-4.88-14.18--12.48--
Medclair Invest AB39.85m-2.79m102.29m14.00--2.0537.202.57-0.0314-0.03140.50800.60560.65041.369.952,846,643.00-4.55-11.20-5.40-12.9562.1469.51-6.99-26.941.08-7.160.0078--60.1352.1444.27--24.59--
Serstech AB62.91m715.00k251.35m21.0093.545.2419.854.000.0130.0130.32880.23211.125.348.342,995,857.001.27-21.121.80-26.6277.2480.731.14-44.612.244.700.0362--267.6542.82102.42--19.34--
Biohit Oyj152.75m21.62m287.83m42.0016.863.2411.121.880.11980.11980.85270.62371.095.103.80--15.47-5.8820.55-7.1964.7363.5214.16-7.473.58--0.0693--19.405.66207.99--75.26--
Data as of Apr 26 2024. Currency figures normalised to Mantex AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.